Can a new drug outperform standard care for a rare liver disease in teens?
NCT ID NCT03678480
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether an experimental drug called HTD1801 can improve liver health in adolescents with primary sclerosing cholangitis (PSC), a rare disease that damages the bile ducts. Participants will receive either HTD1801 or the standard treatment, ursodeoxycholic acid (UDCA), to compare their effects on liver enzyme levels. The study aims to see if HTD1801 can reduce markers of liver damage better than the current therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HTD1801 capsules, 250mg, compared to ursodeoxycholic acid (UDCA) capsules, 125mg
- What this could lead to
- If successful, HTD1801 could offer a new treatment option for adolescents with primary sclerosing cholangitis, potentially improving liver health and slowing disease progression.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not be conclusive. The drug may not prove more effective than UDCA, and there could be unforeseen side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADOLESCENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new molecule tame a rare liver disease? early safety trial begins
- Blood test may tame the tightrope walk of transplant drugs
- Could a trip to the pediatrician help teens beat opioid addiction?
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Could a common drug stop a rare liver disease from returning after transplant?